Evaluation of oncoReveal Essential MPN Panel on Illumina MiSeq i100 for Key Driver Mutation Testing in Myeloproliferative Neoplasms

Mayo Clinic’s Molecular Hematopathology Laboratory evaluated Pillar’s oncoReveal® Essential MPN Panel — a single-tube SLIMamp® amplicon NGS assay targeting JAK2, CALR, and MPL — on the Illumina MiSeq i100 for BCR::ABL1-negative myeloproliferative neoplasm (MPN) testing. Ninety-four peripheral blood and bone marrow specimens were compared against the laboratory’s capture-based myeloid NGS panel, JAK2 V617F allele-specific PCR, CALR fragment analysis, and MPL Sanger sequencing. The panel showed 91–100% concordance across comparators and returned results within 24 hours of extraction, against 5–7 days for the conventional reflex cascade.
Analytical Concordance of NGS-based Tests for ESR1 Mutation Detection in Plasma
Targeted NGS as a Front-Line Strategy to Accelerate the Delivery of Precision Medicine for Solid and Heme Tumors

Publishing Entity: GenomeWeb | Precision Medicine Online
TBC
Utilizing Pillar Biosciences’ Rapid oncoReveal 4-Gene Methylation Panel to Guide PARPi Therapy in Breast Cancer Patients

Event Name: AMP 2024
TBC
The Simple Verifiation in a Molecular Pathology Lab of the FDA Approved oncoReveal CDx Pan-Cancer Solid Tumor IVD Assay

Event Name: AMP 2024
TBC
Leveraging Pillar Biosciences Targeted NGS Panels as a Rapid Front-Line Strategy to Inform and Accelerate the Delivery of Precision Medicine
Event Name: AMP 2024
TBC
Accelerating Access to Liquid Biopsy Testing with Kitted NGS Solutions

Publishing Entity: GenomeWeb | Precision Medicine Online
TBC
Streamlining the Clinical Laboratory Workflow of Myeloproliferative Neoplasms with Next-Generation Sequencing

Publishing Entity: GenomeWeb | Precision Medicine Online
TBC
Need for speed in solid tumor molecular testing
Publication Source: CAP TODAY
TBC
Performance of Pillar oncoReveal Essential MPN Panel: experiences of two clinical diagnostic laboratories

Advocate Health ACL Laboratories and Atrium Health Molecular Pathology jointly validated Pillar’s oncoReveal® Essential MPN Panel across two laboratory sites, replacing the single-gene cascading algorithm conventionally used to test JAK2, CALR and MPL in myeloproliferative neoplasms — a workflow that lengthens turnaround, risks errors from sample splitting, and is expensive to manage. Two hundred thirty-nine clinical blood and bone marrow specimens were sequenced on Illumina MiSeq and NextSeq 550 Dx with PiVAT® reporting, and every identified variant was confirmed by an orthogonal PCR, qPCR or PCR/CE method. Concordance was 100%, repeatability and reproducibility were 100%, and average turnaround shortened by 7–10 days.